AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03265405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medium dose prednisolone
Description: An initial dose of 40 mg/day will be administered for 4 weeks, followed by 30 mg/day for 4 weeks, 20 mg/day for 4 weeks, 15 mg/day for 4 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be tapered over 2 weeks and discontinued.
Study NCT03261557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT + SST
Description: It will consist of 1 individual sessions and 15 weekly periodicity group sessions distributed in 3 modules: cognitive skills module, which includes the basic principles of CBT for psychosis; Social skills module, which includes the usual strategies in HHSS training; and problem solving module.~All patients will receive pharmacological treatment and will be followed up by their referral psychiatrist habitual.
Study NCT06650917 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: the control group were treated with acupoint massage
Description: Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation was used 1 puff each time, 2 times/d.~On this basis, patients in the control group were treated with acupoint massage.
Study NCT03261557 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation, habits and healthy lifestyle
Description: Patients randomized to the control treatment will receive the same number of Individual and group sessions, with the same periodicity and format: 1 individual sessions and 15 weekly periodicity group sessions distributed in 3 modules: psychoeducation, habits and healthy lifestyle.~All patients will receive pharmacological treatment and will be followed up by their referral psychiatrist habitual.
Study NCT01343706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for oral administration
Study NCT01343706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Immediate release solid oral dosage (film-coated tablet)
Study NCT02217657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermocool Smart Touch Catheter
Description: Physician informed to contact force
Study NCT02217657 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermocool Smart Touch Catheter
Description: Physician informed to contact force
Study NCT02392975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fast MR
Description: Enrolled subjects will undergo fast MR within 24 hours of CT completion. Subjects will be scanned using one of 2 Philips Ingenia MR 3T scanners. The estimated duration of the fast MR is less than 5 minutes, even if up to 2 sequences are repeated for motion.
Study NCT01343706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Immediate release solid oral dosage (film-coated tablet)
Study NCT02392975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: The Investigator will recruit children in whom a head CT is ordered as standard of care for TBI. Consenting subjects will undergo fast MR shortly after CT and results will be compared.
Study NCT02460861 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biopsies of the prostatic fossa in Magdeburg
Description: intraoperative Open surgical biopsies of the prostatic fossa after prostatevesiculectomy in Magdeburg
Study NCT01343706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: solution for oral administration
Study NCT03285477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle Ointment was used in participants with Clinically typical AK on the face or scalp.
Study NCT03285477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX2-391 Ointment 1%
Description: The experimental drug, KX2-391 Ointment 1% was used in participants with Clinically typical AK on the face or scalp.
Study NCT01692197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7070
Description: 400 mg/m2 intravenously over 1 hour on Day 1 and Day 8 every 3 weeks.
Study NCT01692197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: 8 mg/m2 by vein over 1 hour daily for 3 days (Days 9-11).
Study NCT01692197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 1.0 g/m2 by vein daily on Days 9 - 12 (age \<60 years) or Days 9 - 11 (age > 60 years).
Study NCT01692197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 10 mg by vein daily for 3 - 4 days with cytarabine.
Study NCT01590641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Ascending Dose (SAD) Cohorts GS-9620
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
Study NCT01590641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Ascending Dose (MAD) Cohorts
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses)
Study NCT02120924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaic acid
Description: Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
Study NCT02120924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
Study NCT02120924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finacea
Description: Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
Study NCT00969852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Multiple doses of 5, 25, and 50 mg Sertraline for 6 days each period.
Study NCT04090944 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) for confirmation of LMA position
Description: -The position of LMA will be assessed by another anesthetist (blinded assessor) using the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) per the grading licensed by Aoyama et al.
Study NCT00829621 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 75 mmHg suction
Description: Incisional Vacuum Assisted Closure (IVAC) Device, set to 75 mmHg suction throughout the duration of the IVAC use.
Study NCT00829621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 125 mmHg
Description: Incisional Vacuum Assisted Closure (IVAC) Device, set to 125 mmHg suction throughout the duration of the IVAC use.
Study NCT01003418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine
Description: Two doses; intramuscular administration
Study NCT01003418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™-IPV/Hib
Description: Routine infant immunisation vaccine, three doses administered intramuscularly
Study NCT01003418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar
Description: Routine infant immunisation vaccine, three doses administered intramuscularly
Study NCT00175136 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Maxim TKA
Description: Operation with Total Knee Arthroplasty and either an I-beam stem or a wedge stem of the tibial component.
Study NCT00578370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin 0.5% (Formulation 01B)
Description: Cutaneous emulsion 200µl once a day (26 days)
Study NCT00578370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin 1.5% (Formulation 02B)
Description: Cutaneous emulsion 200µl once a day (26 days)
Study NCT00578370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% betamethasone
Description: Solution 200µl once a day (26 days)
Study NCT00578370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.005% calcipotriol
Description: Solution 200µl once a day (26 days)
Study NCT00578370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Formulation 00B
Description: Cutaneous emulsion (Vehicle to Formulation 01B and Formulation 02B) 200µl once a day (26 days)
Study NCT04596072 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Chinese traditional rehabilitation
Description: Chinese traditional rehabilitation including acupuncture and herbs
Study NCT02116322 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-FNA with Corkscrew technique
Study NCT02116322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expect 19 G Flex needle
Study NCT00852397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Apixaban 2.5 mg tablet BID for 24 weeks
Study NCT00852397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Apixaban 5.0 mg tablet BID for 24 weeks
Study NCT02460861 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RPVE
Description: Open Radical prostatovesiculectomy in Magdeburg
Study NCT02460861 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ETRARP
Description: Robotassisted Radical prostatovesiculectomy in Gronau
Study NCT00852397 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet for 24 weeks
Study NCT02460861 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CE
Description: Open cystectomy in Magdeburg/Gronau
Study NCT02460861 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biopsies of the prostatic fossa in gronau
Description: intraoperative endoscopic robotassisted biopsies of the prostatic fossa after prostatevesiculectomy in Gronau
Study NCT03712046 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET-CT
Description: Patient will receive one injection of 18F-FDG and then undergo PET-CT imaging
Study NCT04677894 — intervention group
Intervention type: DEVICE
Intervention: Laryngoscopy
Description: During the intubation, the head of the patient was kept in a neutral position, patients were nasotracheally intubated
Study NCT01438541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Window
Description: Dressing
Study NCT02084862 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided percutaneous tracheostomy
Description: Ultrasound guided percutaneous tracheostomy
Study NCT02084862 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy guided percutaneous tracheostomy
Description: Bronchoscopy guided percutaneous tracheostomy
Study NCT04242277 — intervention group
Intervention type: DEVICE
Intervention: Investigational WF-OCT device
Description: Excised lumpectomy tissue will be imaged on an investigational WF-OCT device
Study NCT03859167 — intervention group
Intervention type: OTHER
Intervention: Stress Test
Description: Participants will reach maximum exercise on a treadmill and results will be collected and recorded.
Study NCT01692626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Description: Pimecrolimus 1% topical cream applied twice daily for four weeks on one side of the face.
Study NCT01692626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo cream applied twice daily for four weeks on opposite side of the face from the Pimecrolimus side.
Study NCT04505657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib plus lidocaine
Description: Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
Study NCT04505657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally 2 h before the procedure +Sterile water 4 puffs during the procedure
Study NCT04505657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: placebo to celecoxib administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure
Study NCT01125189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 20 mg, once daily, 12-24 weeks, depending on response
Study NCT01125189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 60 mg, once daily, 12-24 weeks, depending on response
Study NCT01125189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, oral, 0 mg, once daily, 24 weeks
Study NCT01125189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peg-interferon alfa-2a
Description: Syringe, subcutaneous Injection, 180 µg, once weekly, 24 or 48 weeks depending on response
Study NCT01125189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: peg-interferon alfa-2a
Description: Syringe, subcutaneous Injection, 180 µg, once weekly, 24 or 48 weeks depending on response
Study NCT01125189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Tablets, oral, 1000 or 1200 mg based on weight, once daily, 24 or 48 weeks depending on response
Study NCT01125189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ribavirin
Description: Tablets, oral, 1000 or 1200 mg based on weight, once daily, 24 or 48 weeks depending on response
Study NCT03490110 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: State regulation skill training
Description: Participants complete seven supervised training sessions. Training sessions last 2 hours, and participants are requested to complete approximately 2.5 hours of additional skill practice over the course of each week outside of session (total \~4.5 hours per week).
Study NCT03490110 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual
Description: Participants receive clinical care as usual over a matched time period.
Study NCT03835923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Description: intervention phase 1 (baseline - month 6): Patients receive an individual exercise plan, nutritional recommendations and advices to increase daily activity. The intervention is accompanied by regular oral and written feedback.~intervention phase 2 (month 6 - month 12): Patients receive an individual exercise plan, nutritional recommendations and advices to increase daily activity without additional oral or written feedback.
Study NCT03835923 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Recommendation for lifestyle intervention at baseline and after 6 months (e.g. salt reduction, restricted alcohol consumption and smoking cessation, 10,000 steps/day, 150 minutes/week moderate intensity exercise)
Study NCT01459133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin Inhalation System
Description: Single Site, Single Subject use of Technosphere® Insulin Inhalation System
Study NCT01646372 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Simulation Based ACLS Refresher Teaching
Description: 45min-1 hour time. 15 minutes didactic review of 2010 ACLS guidelines followed by practice simulated megacodes
Study NCT01646372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Aid based ACLS Refresher training
Description: 45min-1 hour time. 15 minutes didactic review of 2010 ACLS guidelines followed by simulated ACLS megacode practice focused on the use of Cognitive Aids to guide management.
Study NCT03825354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BIC
Description: World Health Organization, WHO, Brief Intervention and Contact (BIC)
Study NCT01799629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerin suppositories
Study NCT02641743 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inslow
Description: carbohydrate adjusted liquid food using palatinose as the major carbohydrate (>50%)
Study NCT02641743 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: standard balanced formula
Study NCT03271801 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: child health education
Description: 10, 60-minute sessions with a family-based obesity treatment program implemented for the first 40-minutes of each session followed by 20 minutes of education about a child health topic.
Study NCT03271801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: skills training
Description: 10, 60-minute sessions with a family-based obesity treatment program implemented for the first 40-minutes of each session followed by 20 minutes of experiential learning about stimulus control strategies (portion size, energy density, variety).
Study NCT02712320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMIS 50 mg
Description: Subcutaneous injection of 50 mg Leuprolide Mesylate
Study NCT02462798 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Whole grain rye bread
Description: Whole grain rye bread baked without sourdough fermentation (normal yeast-based fermentation)
Study NCT02462798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole grain sourdough rye bread
Description: Whole grain rye bread fermented with sourdough culture before baking
Study NCT04604756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: administration of losartan (50 mg) (oral)
Study NCT04604756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: administration of placebo (oral)
Study NCT02880670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986142
Study NCT03540888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep transverse Friction Massage
Description: The procedure consisted of applying friction massage by fingertips transversely to the hamstrings tendon, in a sitting position. The tendon was located over four finger widths proximal to the medial and lateral epicondyles of the femur
Study NCT03540888 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic stretching intervention
Description: Participants in this group, swung their tested leg actively into hip flexion while keeping their knee fully extended and their ankle fully plantar flexed until a stretch was felt in the posterior thigh. This was repeated over 30 seconds and included in the participant's warm-up phase.
Study NCT03540888 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static stretching intervention
Description: In the static stretching intervention, all participants laid on the floor in a supine position with both feet pointing upwards, with the tested limb in full knee extension and the foot in a relaxed position. The tested limb was moved up passively to a point of slight pain or discomfort at the posterior aspect of the thigh. This technique puts the hamstrings muscle at its greatest possible length. This position should be held for 30 seconds and was performed three times for a total of one minute and 30 seconds, 15 minutes after a match or training. The contralateral leg was stabilized by means of another collaborator in order to prevent compensation by rotation or elevation of the pelvis.
Study NCT00455403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: One tablet of 80 mg of chloroquine on a daily basis for 12 months followed by 12 months off drug with 1 visit at month 24
Study NCT04391582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tilapia skin
Description: After cleaning the lesion with tap water and 2% chlorhexidine gluconate, the tilapia skin was applied and covered with gauze and bandage. These dressings were changed only if the tilapia skin did not adhere properly to the wound bed
Study NCT05958979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Marketing Strategies
Description: Participants will self-administer experimenter-provided e-cigarettes
Study NCT04391582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: silver sulfadiazine cream 1%
Description: After cleaning the lesion with tap water and 2% chlorhexidine gluconate, a thin layer of silver sulfadiazine cream 1% was applied and covered with gauze and bandage. In these patients, the dressings were changed daily
Study NCT01142245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral esomeprazole
Description: • Oral Esomeprazole 40mg on Day 1, 2 and Day 3 q12h
Study NCT01142245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Esomeprazole
Description: Esomeprazole IV 80mg loading bolus~* Esomeprazole intravenous infusion 8mg/hr for 72 hours